PUBLIC COMPANY
save$MRKMerck & Co., Inc.
$MRK152.20+12.60%Rahway, NJ, USupdated 4h ago
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue.
community read0 votes
pipeline
62
marketed
34
phase 3
4
catalysts ytd
16
approvals ytd
9
recalls ytd
0
Pipeline(62)
view full pipeline →pipeline depth62 products
1Preclinical1Phase 111Phase 24Phase 334Marketed9Unknown2pre_registration
Marketed
(berahyaluronidase alfa + pembrolizumab)
Muscle Invasive Bladder Cancer (MIBC)
Marketed(ceftolozane sulfate + tazobactam sodium)
Complicated Intra-Abdominal Infections
Marketed(cilastatin sodium + imipenem + relebactam)
Complicated Intra-Abdominal Infections
Marketed(doravirine + islatravir hydrate)
Human Immunodeficiency Virus (HIV) Infections (AIDS)
Marketed(doravirine + lamivudine + tenofovir disoproxil fumarate)
Human Immunodeficiency Virus (HIV) Infections (AIDS)
Marketed(ertugliflozin + metformin hydrochloride)
Type 2 Diabetes
Marketed(ertugliflozin + sitagliptin phosphate)
Type 2 Diabetes
Marketed(measles [strain Edmonston] + mumps [strain Jeryl Lynn] + rubella [strain Wistar]) vaccine
Measles
Marketed(measles [strain Enders Edmonston] + mumps [strain Jeryl Lynn (Level B)] + rubella [strain Wistar RA 27/3] + varicella [strain Oka/Merck]) vaccine
Measles
Marketed(metformin hydrochloride + sitagliptin phosphate) ER
Type 2 Diabetes
MarketedERTUGLIFLOZIN
Type 2 Diabetes
MarketedEbola Zaire vaccine
Ebolavirus Infections (Ebola Hemorrhagic Fever)
Upcoming
Recent(90d)
view all catalysts →Insider activity
source: SEC Form 4routine RSU / option mechanics (3)
- Mar 31, 26grantGLOCER THOMAS H · director405 sh
- Mar 31, 26grantCoe Mary Ellen · director249 sh
- Mar 31, 26grantSeidman Christine E · director68 sh
🐶 Hiring Signal
next earnings Oct 29, 2026
Where Merck & Co., Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
News
- Attovia adds to biotech IPO momentum with $289M offeringThe startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.biopharma_dive · 14d ago
- J&J pharma leader to retire; Krystal slumps on gene therapy missJennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.biopharma_dive · 15d ago
- FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High CholesterolThe U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduc…fda_press · 1mo ago
- Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast CancerCapivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.onclive · 3mo ago
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that